Navigation Links
Biomerix Receives CE Mark Approval For ASSURE Soft Tissue Repair Mesh
Date:1/5/2012

FREMONT, Calif., Jan. 5, 2012 /PRNewswire/ -- Biomerix Corporation announced today that it has received CE Mark approval  for its ASSURE soft tissue repair mesh, a novel composite mesh intended for the reconstruction of hernias and soft tissue deficiencies and for the temporary bridging of fascial defects.  This approval allows Biomerix to distribute ASSURE throughout Europe and support certification in many other parts of the world that recognize the CE Mark for commercial distribution purposes. 

ASSURE is constructed of three distinct layers, each layer providing an important function in the repair of a hernia or soft tissue deficiency.  The first layer consists of the Biomerix Biomaterial, a proprietary, biointegrative synthetic polyurethane tissue scaffold designed to play a role similar to that of the body's extracellular matrix, a biological structure that supports tissue repair and regeneration.  The second layer is a knitted polypropylene monofilament mesh which provides mechanical support for a strong, durable and flexible repair.  The third layer consists of a resorbable lactide caprolactone copolymer film designed to minimize tissue attachment to the device in case of direct contact with the viscera.

"ASSURE's distinctive multi-layered design reflects extensive market research to address patient comfort and surgeon ease-of-use in open and laparoscopic (minimally invasive) hernia repair procedures.  The device incorporates the unique properties of a biologic tissue scaffold to support tissue regeneration with the best properties of a synthetic biomaterial in terms of its strength and durability," said Kenneth G. Hayes, President and CEO of Biomerix Corporation.  "ASSURE is already available in the United States after receiving a 510(k) clearance from the U.S. Food and Drug Administration (FDA) in May 2010.  We are thrilled with the initial US experience to date and believe that ASSURE will provide substantial clinical benefits to patients."

About Biomerix Corporation

Biomerix Corporation is recognized as a leader in the development and manufacturing of innovative non-absorbable and bioresorbable three-dimensional, open-cell, resilient elastomeric polyurethane biomaterials.  The Company's expertise includes the development, co-development and supply of new proprietary materials, products and components to customers in the medical, industrial and consumer industry markets.

For more information please visit www.biomerix.com or call 888.308.3620.


'/>"/>
SOURCE Biomerix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biomerix Ventral Hernia Repair Mesh Receives FDA 510(k) Clearance
2. Biomerix Granted CE Mark for its REVIVE™ Soft Tissue Repair Mesh
3. Biomerix Awarded Two Device Licenses by Health Canada
4. Biomerix Corporation and Gel Company Announce Strategic Distribution Agreement
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 2016 Transformational M&A achieved through NPS ... --> Transformational M&A achieved through NPS and Dyax ... Transformational M&A achieved through NPS and Dyax acquisitions ... for future growth with most robust pipeline in Shire ... future growth with most robust pipeline in Shire , ...
(Date:2/11/2016)... 11, 2016  AbbVie, a global biopharmaceutical company, ... designed to provide financial support for exceptional students ... higher education goals. Fifteen scholars will be selected ... year. The AbbVie Rheumatology Scholarship is currently accepting ... president, corporate social responsibility, brand and communications, AbbVie. ...
(Date:2/11/2016)... Exactus Pharmacy Solutions, a WellCare (NYSE: ... care for those suffering from long-term, life-threatening or ... Specialty Pharmacy Accreditation from URAC, an independent, nonprofit ... care quality through accreditation, education and measurement. ... URAC accreditation process demonstrates a commitment to quality ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 budget request ... shift more of the cost burden to military beneficiaries. , MOAA’s president, retired ... defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. ...
(Date:2/11/2016)... ... 2016 , ... In a new paper published in the ... Rod J. Rohrich, and colleagues, examine and underscore the importance of upper lateral ... when addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers ...
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD CEO Robert ... will focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities ... practices in data breaches for the Part D Star Rating improvement and Medication ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix today announced ... , will be presenting at the 2016 HIMSS Annual Conference & Exhibition, taking ... During his session, “ Coding for Care: Using Data Analytics for Risk Adjustment ...
(Date:2/11/2016)... ... February 11, 2016 , ... Be Well Medical ... in the heart of Old Town at 108 South Columbus St, Suite 201, Alexandria, ... highest level of medical care in the convenience of their homes, offices or at ...
Breaking Medicine News(10 mins):